Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
GlobalData on MSN5d
Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF
Trevi Therapeutics has finished enrolling subjects in a trial of investigational Haduvio for treating chronic cough in IPF ...
Trevi Therapeutics completes enrollment for Phase 2b trial of Haduvio in cough
Trevi Therapeutics (TRVI)has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with ...
Morningstar6d
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER ...
Mena FN7d
Trevi Therapeutics Completes Enrollment For Phase 2B CORAL Trial Of Haduvio In Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
"The completion of enrollment in the Phase 2b CORAL trial is a significant milestone in the development of Haduvio for patients with idiopathic pulmonary fibrosis suffering from chronic cough ...
Morningstar5d
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release ...
Yahoo Finance11d
Why Trevi Therapeutics (TRVI) Is Advancing Today
Stifel maintained a Buy rating on the shares. Why Stifel Is More Bullish on TRVI With Trevi poised to soon announce data from a trial of its Haduvio drug as a treatment for refractory chronic cough ...